In vitro use of standard fluid infusion central venous catheter for slow continuous ultrafiltration feasibility assessment

Artif Organs. 2022 Aug;46(8):1695-1700. doi: 10.1111/aor.14253. Epub 2022 Apr 20.

Abstract

Background: Slow continuous ultrafiltration (SCUF) by central venous catheter (CVC) for hemodialysis is a simple extracorporeal ultrafiltration that can reduce and control fluid overload in patients with chronic or acute chronic heart failure unresponsive to medical therapy. In order to avoid complications and risks related to the catheterization with a standard CVC for hemodialysis to provide the SCUF, considering that hospitalized patients affected by congestive heart failure commonly undergo CVC placement for medications delivering, we tested an in vitro model to use a standard CVC for infusion to perform SCUF.

Methods: We performed an in vitro SCUF experimental model through two different lumens of a triple (8Fr × 20 cm Tri-lumen catheter Kit-Envans Extra) and a quad-lumen CVC (8.5Fr × 20 cm Quad-lumen catheter kit-Benefis Medical Devices) commonly used in our Intensive Care Unit for fluids and medications infusions. We used Prismaflex with the HF-20 set (Baxter, IL, USA) to perform the SCUF treatment.

Results: Our in vitro data confirm the technical feasibility of the use of standard CVC for fluid infusion to perform a SCUF treatment with a theoretical weight loss of up to 200 ml/h by a blood flow ranging from 30 to 45 ml/min.

Conclusions: The use of standard infusion CVC could be utilized in the intensive care unit to perform SCUF not exposing patients to the risks and complications related to the placement and permanence of CVC for hemodialysis.

Keywords: central venous catheter; chronic heart failure; fluid overload; slow continuous ultrafiltration; ultrafiltration.

MeSH terms

  • Catheterization
  • Catheterization, Central Venous* / adverse effects
  • Central Venous Catheters* / adverse effects
  • Continuous Renal Replacement Therapy*
  • Feasibility Studies
  • Heart Failure* / therapy
  • Hemofiltration* / adverse effects
  • Humans